|Publisher||: Academic Press|
|Release Date||: 2018-11-21|
|ISBN 10||: 0128127384|
|Pages||: 292 pages|
Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment
|Publisher||: Academic Press|
|Release Date||: 2019-10-04|
|ISBN 10||: 0128178698|
|Pages||: 376 pages|
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance. This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites. Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
|Author||: Maie A. St. John,No hee Park|
|Publisher||: Academic Press|
|Release Date||: 2020-06-29|
|ISBN 10||: 0128209291|
|Pages||: 266 pages|
Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients. Covers new chemotherapy trials, specifically on HPV and non-HPV related cancer types Discusses the application of immunotherapy to treat rare types of head and neck cancer Presents updated information on targeted therapies, specifically focusing on skin cancer in the region
|Author||: Joel E. Tepper|
|Publisher||: Elsevier Health Sciences|
|Release Date||: 2019-12-06|
|ISBN 10||: 0323672477|
|Pages||: 1648 pages|
A comprehensive, multidisciplinary resource for the entire radiation oncology team, Gunderson & Tepper’s Clinical Radiation Oncology, 5th Edition, thoroughly covers all aspects of this complex and dynamic field. Concise, templated chapters cover the basic biology of oncologic disease processes as well as updated treatment algorithms, the latest clinical guidelines, and state-of-the-art techniques and modalities. More than 1,000 images—detailed anatomy drawings, radiographic images, and more—provide outstanding visual support for every area of the text. Divides content into three distinct sections for quick access to information: Scientific Foundations, Techniques and Modalities, and Disease Sites. Disease Site chapters include overviews summarizing the most important issues and concluding discussions on controversies and problems. Features new and expanded content on molecular and cellular biology and its relevance in individualized treatment approaches, stereotactic radiation therapy, radiosurgery, proton therapy, biologic therapy, precision radiation therapy, targeted radiation, dosing guidelines for better quality of life and improved patient outcomes, and more. Includes new chapters on Radiation Physics: Particle Therapy, Interventional Radiology, Radiation Therapy in the Elderly, Palliative Care, Quality and Safety, and Immunotherapy with Radiotherapy. Provides guidance on single-modality and combined-modality approaches, as well as outcome data including disease control, survival, and treatment tolerance. Includes access to videos on Intraoperative Irradiation, Prostate Brachytherapy, Penile Brachytherapy, and Ocular Melanoma.
Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.
Using a proven, practical, algorithmic approach, Surgical Decision Making summarizes evidence-based guidelines and practice protocols in an easy-to-follow format. Designed to sharpen the decision-making skills of both trainees and practicing surgeons, the 6th Edition directs your focus to the critical decision points in a wide range of clinical scenarios, helping you determine optimal evaluation and management to secure the best possible patient outcomes. Algorithms are accompanied by annotations that explain all critical factors affecting decisions in a concise, readable manner. Reflects the scope of practice of today’s general surgeon, with fresh, expert perspectives from new editor Dr. Richard Schulick and numerous new contributors. Contains 58 new chapters and thoroughly revised content throughout. Includes new coverage of Preoperative Evaluation of the Geriatric Patient, Pancreatic Cystic Neoplasm, Familial Breast Cancer, Resuscitative Endovascular Balloon Occlusion of the Aorta, Blunt Cerebrovascular Injury, and much more. Uses an easy-to-follow, consistent format, with an algorithm on one page and short descriptions explaining the various steps in the decision-making process on the opposite page. Includes explanatory notes that summarize presenting signs and symptoms, laboratory investigation, diagnostic modalities, surgical therapies, and adjuvant therapies for each condition. Encompasses both general surgery and surgical subspecialties―helping you directly manage a broad range of problems. Emphasizes information that frequently appears on board exams.
To address the growing complexities of childhood cancer, Nathan and Oski’s Hematology and Oncology of Infancy and Childhood has now been separated into two distinct volumes. With this volume devoted strictly to pediatric oncology, and another to pediatric hematology, you will be on the cutting edge of these two fields. This exciting new, full-color reference provides you with the most comprehensive, authoritative, up-to-date information for diagnosing and treating children with cancer. It brings together the pathophysiology of disease with detailed clinical guidance on diagnosis and management for the full range of childhood cancers, including aspects important in optimal supportive care. Written by the leading names in pediatric oncology, this resource is an essential tool for all who care for pediatric cancer patients. Offers comprehensive coverage of all pediatric cancers, including less common tumors, making this the most complete guide to pediatric cancer. Covers emerging research developments in cancer biology and therapeutics, both globally and in specific pediatric tumors. Includes a section on supportive care in pediatric oncology, written by authors who represent the critical subdisciplines involved in this important aspect of pediatric oncology. Uses many boxes, graphs, and tables to highlight complex clinical diagnostic and management guidelines. Presents a full-color design that includes clear illustrative examples of the relevant pathology and clinical issues, for quick access to the answers you need. Incorporates the codified WHO classification for all lymphomas and leukemias.
Peritoneal dissemination is a common route of cancer metastasis. The benefit of administering chemotherapy directly into the peritoneal cavity is supported by preclinical and pharmacokinetic data. In comparison to intravenous (IV) treatment, intraperitoneal (IP) administration results in a several-fold increase in drug concentration within the abdominal cavity. There is now growing evidence from clinical studies showing a survival advantage for IP chemotherapy in various tumor typies, including ovarian, gastric and colorectal cancer. However, while the use of IP chemotherapy is slowly gaining acceptance, it is not universal, largely due to the greater toxicity associated with this approach. Moreover, efficacy of IP chemotherapy is limited by poor distribution within the abdominal cavity and by poor tissue penetration. A new way of IP chemotherapy is the application of cytotoxics in form of a pressurized aerosol into the abdominal of thoracic cavity. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is applied through laparoscopic access using two balloon trocars in an operating room equipped with laminar air-flow. In a first step,a normothermic capnoperitoneum is established with a pressure of 12 mmHg. A cytotoxic solution (about 10% of a normal systemic dose) is nebulized with a micropump into the abdominal cavity, and maintained for 30 min. The aerosol is then removed through a closed suction system. Applying an aerosol in the peritoneal cavity allows a homogeneous distribution of the chemotherapeutic agent within the abdomen. Furthermore, an artificial pressure gradient is generated that overcomes tumoral interstitial fluid pressure, an obstacle in cancer therapy. This results in a higher local drug concentration compared to conventional IP or IV chemotherapy. At the same time the plasma concentration of the chemotherapeutic agent remains low. In first clinical studies with limited number of patients in ovarian, gastric and colorectal cancer, as well as peritoneal mesothelioma, PIPAC has obtained encouraging tumor response rates and survival, with a low-side effects profile. Larger clinical trials are currently ongoing to examine if these data can be reproduced and extrapolated to other situations.
Early detection of cancer at the cellular level, even before anatomic anomalies are visible, is critical to more efficacious and cost effective diagnosis and therapeutic advances. In Cancer Nanotechnology: Methods and Protocols, an international panel of experts provide the most recent, cutting-edge, "how-to" approaches developed and employed by researchers in a variety of disciplines to identify cancer specific biomarkers, construct suitable multifunctional targeted nanostructure platforms, along with enhanced imaging and therapeutic applications. Covering such topics as multifunctional and multimodal nanoparticles, nanoparticle mediated cancer theranostics, molecular targets for cancer nanotechnology, and nanoparticles for non-invasive image-guided cancer therapy, the volume addresses the key challenges of the field today, specifically targeted and localized delivery of the drugs. As a volume in the highly successful Methods in Molecular BiologyTM series, the protocols chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Cancer Nanotechnology: Methods and Protocols integrates cancer biology, clinical oncology, molecular cancer imaging, materials science and chemical engineering, biomedical engineering, toxicology, computer science, electrical engineering, chemistry, physics, and mathematics in order to achieve the vital goals of nanotechnology-mediated early cancer detection and more efficacious and less toxic therapies for these devastating diseases.
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book “Targeted Radionuclide Tumour Therapy – Biological Aspects” was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.
This important reference provides up-to-date information on all aspects of ribosome-inactivating proteins (RIPs). Including a list of all known RIPs, their distribution in nature, structure, genetics and chemical and immunological properties, this reference covers mechanisms of action, including the enzymatic activity on various polynucleotide substrates; the interaction with, and entry into cells; the toxicity to animals, including the pathology of poisoning; and the immunomodulatory and allergenic activity. The book further emphasizes the use of immunotoxins and other conjugates in clinical trials for the therapy of cancer and intractable pain.
The use of copper, silver, gold and platinum in jewelry as a measure of wealth is well known. This book contains 19 chapters written by international authors on other uses and applications of noble and precious metals (copper, silver, gold, platinum, palladium, iridium, osmium, rhodium, ruthenium, and rhenium). The topics covered include surface-enhanced Raman scattering, quantum dots, synthesis and properties of nanostructures, and its applications in the diverse fields such as high-tech engineering, nanotechnology, catalysis, and biomedical applications. The basis for these applications is their high-free electron concentrations combined with high-temperature stability and corrosion resistance and methods developed for synthesizing nanostructures. Recent developments in all these areas with up-to-date references are emphasized.